Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound racanisodamine eye drops

A technology of anisodamine and eye drops, which is applied in the direction of pharmaceutical formulations, medical preparations of non-active ingredients, peptide/protein components, etc., can solve problems such as eye discomfort, low distance vision, and limited efficacy, and achieve the elimination of eye discomfort , the control effect is obvious, the control effect is effective

Inactive Publication Date: 2021-02-12
ZHENJIANG HENGXIN PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] In recent years, with the acceleration of social modernization and the continuous improvement of people's living standards, the incidence of myopia has continued to increase. Myopia has become one of the eye diseases with the highest incidence in the world today; remarkable achievements have been made in the prevention and treatment of common diseases among students However, the myopia rate of students continues to rise. Research statistics show that because primary school students are still in the developmental stage, the eye structure is extremely unstable, and they are prone to pseudomyopia. If it is not controlled, it will develop rapidly. High myopia, the adjustment function of the high myopia is weak, and the atrophy of the adjustment muscles can be measured, and as various electronic devices such as computers, mobile phones, and electronic game consoles enter society and families, these electronic devices are bringing great benefits to people's work and study. At the same time of convenience, it also has some impact on people's eyesight, especially the eye fatigue caused by excessive use of eyes by young children due to long-term use of these electronic devices is an important factor for the current increase in the incidence of myopia among young people; pseudomyopia is a kind of Temporarily reversible myopia, the patient's distance vision is lower than normal, and the myopia disappears after the accommodation spasm is relieved, showing emmetropia or hyperopia. The duration of pseudomyopia is generally several weeks to several months. This stage is also the best time to implement clinical treatment measures. The best time, if not actively treated, it is very easy to develop into true myopia, which will have a significant impact on the vision of young people;
[0003] The existing eye drops for the treatment of eye fatigue and the prevention and treatment of pseudomyopia in adolescents are relatively single in composition, which leads to relatively single drug properties and limited efficacy, and cannot achieve true treatment of pseudomyopia and prevention of true myopia. For the purpose of treatment, the method of increasing the dosage is generally adopted, which often causes more discomfort to the eyes, causes adolescents to have resistance during the treatment process, and leads to interruption of treatment. Therefore, it is necessary to provide a safe and reliable Eye drops is an urgent problem to be solved clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound racanisodamine eye drops
  • Compound racanisodamine eye drops
  • Compound racanisodamine eye drops

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The compound racemic anisodamine eye drops is made from the following raw materials: racemic anisodamine 0.018 wt%, tropicamide 0.005 wt%, sodium chondroitin sulfate 1.9 wt%, diclofenac sodium 0.15 wt%, recombinant Human epidermal growth factor 0.12wt%, sodium chloride 0.84wt%, thimerosal 0.008wt%, pH regulator to adjust pH to 5.5-6.5, water for injection balance;

Embodiment 2

[0022] The compound racemic anisodamine eye drops is made from the following raw materials: racemic anisodamine 0.012 wt%, tropicamide 0.007 wt%, sodium chondroitin sulfate 2.2 wt%, diclofenac sodium 0.33 wt%, recombinant Human epidermal growth factor 0.09wt%, sodium chloride 1.18wt%, thimerosal 0.008wt%, pH regulator to adjust pH to 5.5-6.5, water for injection balance;

Embodiment 3

[0024] The compound racemic anisodamine eye drops is made from the following raw materials: racemic anisodamine 0.014 wt%, tropicamide 0.005 wt%, sodium chondroitin sulfate 2.6 wt%, diclofenac sodium 0.28 wt%, recombinant 0.13wt% of human epidermal growth factor, 1.05wt% of sodium chloride, 0.011wt% of thimerosal, a pH regulator to adjust the pH to 5.5-6.5, and the balance of water for injection;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is compound racanisodamine eye drops prepared from the following raw materials: 0.010-0.02 wt% of racanisodamine, 0.005-0.01 wt% of tropicamide, 1.5-2.8 wt% of sodium chondroitin sulfate, 0.05-0.4 wt% of diclofenac sodium, 0.05-0.15 wt% of a recombinant human epidermal growth factor, 0.72-1.25 wt% of sodium chloride, 0.005-0.012 wt% of thiomersalate, a pH regulator for adjusting pH to 5.5-6.5, and the balance being injection water. The compound racanisodamine eye drops disclosed by the invention are applied to adolescents, children and adults who often use eyes at a short distance, sothat the delaying and preventing effects on myopia of the adolescents and children are more obvious and effective after the compound racanisodamine eye drops are dripped for a long time, and for adults, visual fatigue can be significantly improved, and the elimination of eyeball discomfort and other symptoms can be accelerated; diclofenac sodium and racemic anisodamine are combined to achieve a good synergistic effect, diclofenac sodium is used as a ligand and matched with racemic anisodamine to generate a synergistic effect of biological activity, and meanwhile, diclofenac sodium and racemicanisodamine have the possibility of reducing toxicity, are low in price and easy to obtain and are worthy of popularization clinically.

Description

technical field [0001] The present invention relates to the technical field of ophthalmic drug production of pharmaceutical preparations, more specifically relate to a kind of compound racemic anisodamine eye drops. Background technique [0002] In recent years, with the acceleration of social modernization and the continuous improvement of people's living standards, the incidence of myopia has continued to increase. Myopia has become one of the eye diseases with the highest incidence in the world today; remarkable achievements have been made in the prevention and treatment of common diseases among students However, the myopia rate of students continues to rise. Research statistics show that because primary school students are still in the developmental stage, the eye structure is extremely unstable, and they are prone to pseudomyopia. If it is not controlled, it will develop rapidly. High myopia, the adjustment function of the high myopia is weak, and the atrophy of the adj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K38/18A61K47/36A61P27/02A61P27/10A61K31/196A61K31/4409A61K31/46
CPCA61K31/46A61K31/4409A61K31/196A61K38/1808A61K9/08A61K9/0048A61K47/36A61P27/10A61P27/02A61K2300/00
Inventor 朱永星樊海声张鹏陈娟
Owner ZHENJIANG HENGXIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products